Eli Lilly Pauses Enrollment in ACTIV-3 Clinical Trial Due to Safety Concerns

Shots:  The independent DSMB recommended pausing the enrollment of the ACTIV-3 clinical trial. The trial is evaluating Lilly’s bamlanivimab (LY-CoV555, 7000mg) + remdesivir as a treatment for COVID-19 in hospitalized patients, and is sponsored by the NIAID Lilly trusts the judgment & supports independent DSMB decisions to exercise caution in ensuring the safety of the …

Eli Lilly Pauses Enrollment in ACTIV-3 Clinical Trial Due to Safety Concerns Read More »